Douglas C. Bauer, MD

Dr. Bauer was a member of the Planning Committee of the NIH Consensus Conference on Osteoporosis, and the Advisory Committee on Biochemical Markers of Bone Turnover of the National Osteoporosis Foundation. He continues to serve on the NOF Scientific Advisory Committee and is an ad-hoc member of the NIH Skeletal Biology, Disease and Development Study Section. Dr. Bauer serves as Chair for several NIH funded trials. Dr. Bauer is an Associate Editor for the Primer on Metabolic Bone Diseases and Disorders of Mineral Metabolism, 8^th Edition and serves on the Editorial Board of the Journal of Clinical Endocrinology and Metabolism and Biomarker Insights. He also maintains a general medical practice at UCSF.

Research Interests

• Osteoporosis risk factors, diagnostic evaluation, treatment
• Biomarkers
• Thyroid dysfunction and treatment
• Epidemiologic and clinical trial methods

Selected Publications

1. Black DM, Kelly MP, Genant HK, Palermo L, Eastell R, Bucci-Rechtweg C, Cauley J, Leung PC, Boonen S, Santora A, de Papp A, Bauer DC; the Fracture Intervention Trial and HORIZON Pivotal Fracture Trial Steering Committees. Bisphosphonates and Fractures of the Subtrochanteric or Diaphyseal Femur. N Engl J Med. 2010 Mar 24. [Epub ahead of print]
2. Schafer AL, Vittinghoff E, Ramachandran R, Mahmoudi N, Bauer DC. "Laboratory reproducibility of biochemical markers of bone turnover in clinical practice." Osteoporos Int. 2010 Mar;21(3):439-45.
3. Bauer DC, Garnero P, Harrison S, Cauley J, Eastell R, Ensrud K, Orwoll E; for the Osteoporotic Fractures in Men (MrOS) Research Group. "Biochemical Markers of Bone Turnover, Hip Bone Loss and Fracture in Older Men: The MrOS Study." J Bone Miner Res. 2009 Dec;24(12):2032-38.
4. Bell KJ, Hayen A, Macaskill P, Irwig L, Craig JC, Ensrud K, Bauer DC. "Value of routine monitoring of bone mineral density after starting bisphosphonate treatment: secondary analysis of trial data." BMJ. 2009 Jun 23;338:b2266.
5. Bauer DC, Ewing SK, Cauley JA, Ensrud KE, Cummings SR, Orwoll ES for the Osteoporotic Fractures in Men (MrOS) Research Group. "Quantitative ultrasound predicts hip and non-spine fracture in men: the MrOS study." Osteoporos Int. 18(6):771-77, 2007.
6. Vittinghoff E, Bauer DC. "Case-only analysis of treatment-covariate interactions in clinical trials." Biometrics. 62(3):769-76, 2006.
7. Bauer DC, Garnero P, Hochberg MC, Santora A, Delmas P, Ewing SK, Black DM. "Pretreatment levels of bone turnover and the antifracture efficacy of alendronate: the Fracture Intervention Trial." J Bone Miner Res, 21:292-99, 2006.
8. Bauer DC, Hochberg M, Ott S, Orloff J, Thompson DE, Ewing SK, Delmas PD. "Change in bone turnover and hip, non-spine, and vertebral fracture in alendronate-treated women: the Fracture Intervention Trial." J Bone Miner Res, 19:1250-8, 2004.
9. Bauer DC, Browner WB, Stone K, "Quantitative ultrasound predicts mortality as well as bone mineral density: the Study of Osteoporotic Fractures." Osteoporosis International, 13:606-612, 2002.
10. Bauer DC, Ettinger B, Nevitt MC, Stone K, "Risk of fracture in women with low serum levels of thyroid-stimulating hormone." Annals of Internal Medicine, 134:561-568, 2001.